FeesSafety
Pluang+

IDEAYA plans Phase 3 trials for IDE849 to treat refractory neuroendocrine carcinomas with potential accelerated FDA approval.

Market News
16 Nov 2026, 23:05 WIB
PRNewsWire
View Source
Bullish
IDEAYA plans Phase 3 trials for IDE849 to treat refractory neuroendocrine carcinomas with potential accelerated FDA approval.

IDEAYA Biosciences announced plans to initiate registrational Phase 3 trials for IDE849, an investigational antibody drug conjugate targeting DLL3, in refractory neuroendocrine carcinomas (NEC) and extensive-stage small cell lung cancer (ES-SCLC) by the end of 2026. The company aims to support accelerated FDA approval through a single-arm extension cohort in gastroenteropancreatic NEC (GEP-NEC) patients, with overall response rate as the primary endpoint. IDE849 has shown promising clinical results, including a 52.6% overall response rate and manageable safety profile in early trials. Following accelerated approval, a randomized Phase 3 trial will confirm clinical benefits and support full approval, expanding treatment options for aggressive NEC subtypes with limited therapies.

IDEAYA Biosciences' recent FDA meeting on IDE849 trial designs provides context for health sector activity on Pluang. As of Nov 17, 2026 03:31 WIB, 31 of 150 priced US health stocks rose while 118 fell. Notable movers include NUWE at USD 4.53 with a -7.55% change and a typical hold time of 33 days, and ACB at USD 4.60 with a -6.88% change and 100% sell order activity.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App